Treats primary dysmenorrhea. ANDA 215750, held by Umedica. Diclofenac Potassium.
As of Nov 16, 2026, ANDA 215750 (Diclofenac Potassium), held by Umedica, was first approved by FDA on May 11, 2022, with 2 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Carefully consider the potential benefits and risks of diclofenac potassium immediate-release tablets and other treatment options before deciding to use diclofenac potassium tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS; Gastrointestinal Bleeding, Ulceration, and Perforation ). Diclofenac potassium tablets are indicated: For treatment of primary dysmenorrhea For relief of mild to moderate pain For relief of the signs and symptoms of osteoarthritis For relief of the signs and symptoms of rheumatoid arthritis
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 11, 2022 | Original application | Approved | None posted |
| Diclofenac Potassium50MG · tablet;oral | Diclofenac Potassium | Rx |
| Diclofenac Potassium25MG · tablet;oral | Diclofenac Potassium | Rx |
| Jun 30, 2025 | Supplement 8Manufacturing | Approved | None posted |
| Nov 21, 2024 | Supplement 7Labeling · Standard review | Approved | None posted |
| May 11, 2022 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters